[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335531-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335531-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","nf-b-activated-oncogene-inhibition-strategy-for-cancer-gene-therapy","NF-κB-activated oncogene inhibition strategy for cancer gene therapy","","NF-κB is a high-potential target in cancer because it is overactivated across many tumor types, yet most NF-κB inhibitors fail to reach clinical use due to side effects. This study introduces HOPE, which uses an NF-κB-specific DMP promoter to activate exogenous CRISPR-Cas13a effector expression in cancer cells, then suppresses oncogenic mRNA from TERT, PLK1, KRAS, and MYC. HOPE shows selective antitumor killing in vitro and, when delivered by rAAV-HOPE, significantly inhibits colorectal tumor growth in mice without side effects. scRNA-seq indicates HOPE activates immune responses and reduces cancer cell proportion, including lowered stemness.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nf-b-activated-oncogene-inhibition-strategy-for-cancer-gene-therapy/335531/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nf-b-activated-oncogene-inhibition-strategy-for-cancer-gene-therapy/335531.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the HOPE strategy in this study?","Question",{"text":63,"@type":64},"HOPE activates an exogenous CRISPR-Cas13a effector gene inside cancer cells using an NF-κB-specific DMP promoter, and then suppresses oncogene expression at the mRNA level.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which oncogenes are targeted by HOPE?",{"text":68,"@type":64},"HOPE targets and suppresses the mRNA expression of TERT, PLK1, KRAS, and MYC.",{"name":70,"@type":61,"acceptedAnswer":71},"How was HOPE delivered and tested in vivo?",{"text":72,"@type":64},"HOPE was packaged into an adeno-associated virus (AAV) vector and administered intravenously to mice bearing subcutaneous colorectal cancer transplants to assess tumor growth and side effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335531,1790113069,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cgt](www.nature.com/cgt) Cancer Gene Therapy  \nARTICLE OPEN   \nNF-κB-activated oncogene inhibition strategy for cancer gene therapy  \nWei Dai1,8, Jian Wu 2,8 ✉ , Yingchun Shui3, Qiuyue Wu4,5, Jinke Wang 6 ✉ and Xinyi Xia 4,7 ✉  \n© The Author(s) 2024  \n\n|  |  |  |\n| --- | --- | --- |\n|  | NF-κB is a promising target for cancer treatment because of its overactivation in almost all cancers but countless NF-κB inhibitors rarely became clinical drugs due to side effects. In contrast to traditional cancer treatments aimed at inhibiting NF-κB activity, this study develop a novel approach termed HOPE, which focuses on activating the exogenous effector gene CRISPR-Cas13a within cancer cells, achieved by utilizing the NF-κB-speciﬁc promoter DMP previously constructed, then targets and suppresses the expression of oncogenes TERT, PLK1, KRAS and MYC at mRNA level. We evaluated the antitumour effects of HOPE in various cultured cells and conﬁrmed it could induce obvious the death of cancer cells without affecting normal cells. By packaging HOPE into adenoassociated virus (AAV) and intravenously injected it to treat mice that were subcutaneously transplanted with colorectal cancer. This validated that rAAV-HOPE could signiﬁcantly inhibit tumour growth without side effects. Based on the scRNA-seq data, we observed that HOPE could activate the immune system and decrease the proportion of cancer cells, particularly reducing the stemness of cancer cells. This study elucidates an important role of HOPE in inhibiting cancer cell growth both in vitro and in vivo, additionally provides a novel therapeutic technology for cancer gene therapy.\u003Cbr>Cancer Gene Therapy (2024) 31:1632–1645; [https://doi.org/10.1038/s41417-024-00828-x](https://doi.org/10.1038/s41417-024-00828-x) |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n\nGraphical Abstract  \nFunctional element structure  \nDecoy Minimal Promoter (DMP)  \nNF-κB decoy Minimal promoter  \nU6P  \ngRNA  \nCas13a  \nPlasmid construction  \npAAV-HOPE 7704 bp  \nAAV virus  \nTransfection  \nCancer cells Normal cells  \n1School of Animal Science and Food Engineering, Jinling Institute of Technology, Nanjing 210038, China. 2Department of Bioinformatics, Nanjing Medical University, Nanjing 211166, China. 3Department of Obstetrics, BenQ Medical Center, The Afﬁliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, China. 4Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China. 5State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China. 6School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. 7State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing 210093, China. 8These authors contributed equally: Wei Dai,  \nJian Wu. ✉[email: wujian@njmu.edu.cn](email: wujian@njmu.edu.cn); [wangjinke@seu.edu.cn](wangjinke@seu.edu.cn); [xinyixia@nju.edu.cn](xinyixia@nju.edu.cn)  \nReceived: 27 March 2024 Revised: 20 August 2024 Accepted: 21 August 2024  \nPublished online: 3 September 2024  \nINTRODUCTION  \nDespite the continuous progress in its prevention, diagnosis and treatment, cancer remains a major public health problem worldwide. According to GLOBOCAN data released by the International Agency for Research on Cancer (IARC), 19.2 million new cancer cases and 9.9 million deaths from cancer were reported in 2020 [1]. Traditional cancer therapies, including surgery, chemotherapy, radiotherapy, and the new modality of immunotherapy, have been explored in attempts to improve the quality of life and survival of cancer patients. However, current cancer therapies still have major limitations, such as systemic toxicity, drug resistance, the risk of recurrence and low res","cbCaij3rfNPd5pEO","https://ap.wps.com/l/cbCaij3rfNPd5pEO","pdf",6824269,14,"English","# Introduction\n## NF-κB as a cancer target and its therapeutic limitations\n## HOPE concept and CRISPR–Cas gene-editing background","[{\"question\":\"What is the HOPE strategy in this study?\",\"answer\":\"HOPE activates an exogenous CRISPR-Cas13a effector gene inside cancer cells using an NF-κB-specific DMP promoter, and then suppresses oncogene expression at the mRNA level.\"},{\"question\":\"Which oncogenes are targeted by HOPE?\",\"answer\":\"HOPE targets and suppresses the mRNA expression of TERT, PLK1, KRAS, and MYC.\"},{\"question\":\"How was HOPE delivered and tested in vivo?\",\"answer\":\"HOPE was packaged into an adeno-associated virus (AAV) vector and administered intravenously to mice bearing subcutaneous colorectal cancer transplants to assess tumor growth and side effects.\"}]","NF-κB-activated oncogene inhibition strategy for cancer gene therapy | PDF",1790011327,35]